Advances in Ovarian Cancer Treatment: Past, Present and Future
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 4136
Special Issue Editors
Interests: gynecological oncology; ovarian cancer; endometrial cancer; cervical cancer; vulvar cancer; cytoreductive surgery; HIPEC; minimal invasive surgery
Interests: gynecological oncology; ovarian cancer; endometrial cancer; cervical cancer; vulvar cancer; breast cancer; cytoreductive surgery; minimal invasive surgery
Special Issue Information
Dear Colleagues,
Ovarian cancer is the most lethal gynecological malignancy in relation to cervical and endometrial cancers. It is associated with the worst prognosis and a high mortality rate. In most cases (75%), ovarian cancer is diagnosed at an advanced stage due to its asymptomatic and silent growth of the tumor, delayed onset of symptoms and lack of proper screening.
However, important steps have been made in the treatment of advanced ovarian cancer concerning surgery, adjuvant or neoadjuvant chemotherapy drug regiments and maintenance targeted therapy. These resulted in an improved progression-free and overall survival, and a better quality of life of these patients. Nevertheless, even with the new treatment improvements, 80% of the patients will experience recurrence.
This Special Issue aims to highlight the current practice and advances in ovarian cancer treatment, including cytoreductive surgery, HIPEC, new chemotherapeutic agents and maintenance targeted therapy.
Dr. Dimitrios Tsolakidis
Dr. Dimitrios Zouzoulas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- cytoreductive surgery
- HIPEC
- chemotherapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
